GlassScriptPhysician profile
Judith Johns
NPI 1689965873
$3,981.71
in general payments reported to CMS, 2019-2025
37 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $34.61 · 2024: $1,015 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.48 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $799.19 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $333.06 | 2021-2025 | |
| Lundbeck LLC | $256.03 | 2024-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $232.32 | 2024-2025 | |
| Biogen, INC. | $184.17 | 2024-2025 | Vumerity, Skyclarys |
| Jazz Pharmaceuticals INC. | $182.71 | 2024-2025 | |
| Genentech USA, INC. | $181.19 | 2025 | Ocrevus Zunovo, Evrysdi, Ocrevus |
| Novartis Pharmaceuticals Corporation | $121.86 | 2024-2025 | |
| Corium, LLC | $116.22 | 2024-2025 | Azstarys |
| Lilly USA, LLC | $115.68 | 2024-2025 | Amyvid, Kisunla, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.50 | 2025 | Caplyta |
| Pfizer INC. | $104.81 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $101.26 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $93.65 | 2024-2025 | Auvelity, Symbravo |
| Alexion Pharmaceuticals, INC. | $89.15 | 2024-2025 | Ultomiris |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $85.49 | 2024-2025 | Crexont |
| Alkermes, INC. | $77.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.89 | 2024-2025 | Wainua |
| Grifols USA, LLC | $68.72 | 2025 | Gamunex-C |
| E.R. Squibb & Sons, L.L.C. | $61.41 | 2024 | Cobenfy |
| Acadia Pharmaceuticals INC | $57.30 | 2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $55.93 | 2024-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $53.01 | 2024-2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $52.21 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $47.68 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $41.94 | 2025 | |
| Sk Life Science, INC. | $41.26 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $38.91 | 2025 | Bafiertam |
| Tris Pharma INC | $33.01 | 2025 | Dyanavel Xr |
| Eisai INC. | $31.09 | 2025 | |
| Merz Pharmaceuticals, LLC | $24.93 | 2025 | Ampyra, Inbrija, Xeomin |
| Mdd US Operations, LLC | $24.49 | 2025 | |
| Scilex Pharmaceuticals INC. | $23.81 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $19.39 | 2025 | |
| Neurelis, INC. | $17.58 | 2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $16.33 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.62 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.